Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of sotatercept added to standard therapy in pulmonary arterial hypertension
MOH_2018-07-17_002499Phase 2Recruiting
- Sponsor
- Acceleron Pharma
- Start
- Jun 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotatercept in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Acceleron Pharma. Started Jun 2018; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2018-07-17_002499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-17_002499.